8 results on '"Monte-Neto, Rubens L."'
Search Results
2. Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony.
- Author
-
Moreira, Douglas S., Monte Neto, Rubens L., Andrade, Juvana M., Santi, Ana Maria M., Reis, Priscila G., Frézard, Frédéric, and Murta, Silvane M.F.
- Abstract
Highlights: [•] Level of expression of Pgp is increased in the SbIII-resistant L. guyanensis and L. amazonensis lines. [•] Incorporation of antimony was reduced in the SbIII-resistant L. guyanensis, L. amazonensis and L. braziliensis lines. [•] Down-regulation of AQP1 protein was observed in the SbIII-resistant L. guyanensis and L. amazonensis lines. [•] Rates of SbIII efflux are higher in the SbIII-resistant lines of L. guyanensis and L. braziliensis. [•] Mechanisms of antimony-resistance of the MRPA gene are different among species of Leishmania analyzed. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
3. Validation of a colorimetric LAMP to detect Loxosceles experimental envenomation.
- Author
-
Fernandes, Luana Paula, Rocha, Marcele Neves, Duarte, Clara Guerra, Minozzo, João Carlos, do Monte-Neto, Rubens L., and Felicori, Liza F.
- Subjects
- *
LOXOSCELES , *IDENTIFICATION of animals , *NUCLEIC acid amplification techniques , *DNA , *GENE amplification , *HAIR - Abstract
Diagnostic tests for brown spider accidents are unavailable and impact treatment decisions, increasing costs and patient risks. In this work, we used for the first time a fast, simple, and visual method based on the loop-mediated isothermal amplification assay (LAMP) to detect Loxosceles envenomation. Using the DNA from L. similis legs, we observed a high sensitivity using this test since as low as 0.32 pg of DNA could be detected. This pH-dependent colorimetric assay was 64 times more sensitive than PCR to detect spider DNA. The test was specific for Loxosceles once no cross-reaction was observed when testing DNA from different agents that cause similar dermonecrotic injuries. The test allowed the detection of Loxosceles intermedia DNA from hair, serum, and exudate samples obtained from experimentally-envenomed rabbit within 72 h. The method sensitivity varied according to the sample and the collection time, reaching 100% sensitivity in serum and hair, respectively, 1 h and 24 h after the experimental envenomation. Due to its ease of execution, speed, sensitivity, and specificity, LAMP presents an excellent potential for identifying Loxosceles spp. Envenomation. This can reduce the burden on the Health System and the morbidity for the patient by implementing the appropriate therapy immediately.In addition, this work opens up the perspective to other venomous animal accident identification using LAMP. [Display omitted] • Using 28S primers it was possible to identify L. similis' DNA with high sensitivity. • LAMP was 62-fold more sensitive than PCR and detected as low as 0.32 pg of DNA. • LAMP detected L. intermedia DNA from hair, serum, and exudate from experimentally-envenomed rabbits. • LAMP presents an excellent potential for identifying Loxosceles spp. Envenomation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.
- Author
-
Rugani, Jeronimo N., Quaresma, Patrícia F., Gontijo, Célia F., Soares, Rodrigo P., and Monte-Neto, Rubens L.
- Subjects
- *
LEISHMANIA , *ANTIPROTOZOAL agents , *ANTIMONY , *LEISHMANIASIS , *CUTANEOUS manifestations of general diseases , *GENETIC markers - Abstract
Graphical abstract Highlights • Atypical lesion-derived L. braziliensis are resistant to antimony. • L. braziliensis isolated from atypical cutaneous manifestations presented reduced infection rate in vitro. • Molecular markers from atypical lesion-derived L. braziliensis can beestablished to predict antimony resistance. Abstract Leishmania (Viannia) braziliensis is the most common etiological agent of cutaneous and mucocutaneous leishmaniasis (MCL) in Latin America. An interesting aspect of the disease outcome caused by this species is the appearance of non-ulcerated atypical cutaneous leishmaniasis. Atypical (AT) lesions are often associated with therapeutic failure when treated with antimony(Sb)-based drugs. Refractory cases are not necessarily due to intrinsic parasite drug resistance. The status of in vitro drug susceptibility from L. braziliensis field isolates is less assessed than patient treatment outcome. In this work, L. braziliensis isolated from typical CL (6), MCL (1) and AT (3) lesions and vector (1) were tested for their susceptibility to amphotericin B (AmB), miltefosine (MIL), glucantime (GLU) and non-comercial meglumine antimoniate (MA). Overall, intracellular amastigotes of all isolates were sensitive to the tested antileishmanial drugs except AT lesions-derived strains 316, 330 and 340 that presented in vitro resistance against SbV-based drugs. Although susceptible to miltefosine – based on phenotypic screening – intramacrophagic quiescent amastigotes could restore infection. L. braziliensis promastigotes isolated from AT lesions also displayed 29% reduced capacity to infect human monocyte-derived macrophages when compared with parasites obtained from patients with typical lesions, MCL or from sand-fly. These data indicate differences in drug susceptibility and infectiveness among L. braziliensis isolated from patients exhibiting different types of lesions and highlight the importance of its characterization for drug response prediction outcome in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against SbIII-sensitive and -resistant parasites.
- Author
-
Lizarazo-Jaimes, Edgar H., Reis, Priscila G., Bezerra, Filipe M., Rodrigues, Bernardo L., Monte-Neto, Rubens L., Melo, Maria N., Frézard, Frédéric, and Demicheli, Cynthia
- Subjects
- *
HETEROCYCLIC chemistry , *LIGANDS (Biochemistry) , *ANTI-infective agents , *LEISHMANIA , *DRUG resistance , *THERAPEUTIC use of antimony , *THERAPEUTICS , *PROTOZOA - Abstract
Abstract: Novel trivalent antimony complexes with the nitrogen donor heterocyclic ligand 2,2′-bipyridine (bipy), 1,10-phenanthroline (phen) or dipyrido[3,2-d:2′,3′-f]quinoxaline (dpq) have been synthesized by the reaction with SbCl3 or PhSbCl2. The crystal structures of [Sb(phen)Cl3] and [PhSb(phen)Cl2]CH3COOH were determined and shown to adopt a distorted square pyramid geometry with a five-coordinated Sb center. Surprisingly, all the complexes, the ligands and PhSbCl2 showed very high antileishmanial activities, with IC50 in the nanomolar range against SbIII-sensitive and -resistant Leishmania infantum (syn. Leishmania chagasi) and Leishmania amazonensis strains. These compounds were much more active against these Leishmania strains than the old trivalent drug potassium antimonyl tartrate. [PhSb(phen)Cl2]CH3COOH complex was found to be the most active compound and the lack of cross-resistance of PhSbCl2 suggests that the transport pathways of this compound across the cell membrane differ from those responsible for the resistance of Leishmania to Sb(OH)3. In the case of the complexes with PhSbCl2, our data supports the model that both ligand and metal contributed to the overall activity of the complex. Furthermore, among the complexes with SbCl3, only bipy showed an improved activity upon complexation. Cytotoxicity evaluations of these compounds against murine peritoneal macrophages showed high selective indexes in the range of 7–70 for [Sb(phen)Cl3], [Sb(bipy)Cl3] and [Sb(dpq)Cl3] complexes, being much more selective than potassium antimonyl tartrate. In conclusion, this study presents a set of new antileishmanial agents including one of the most active Sb-based compounds ever reported, which can contribute to the development of new chemotherapeutic strategies against leishmaniasis including Sb-resistant cases. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
6. Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: Synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide–alkyne cycloaddition.
- Author
-
Guimarães, Tiago T., Pinto, Maria do Carmo F.R., Lanza, Juliane S., Melo, Maria N., do Monte-Neto, Rubens L., de Melo, Isadora M.M., Diogo, Emilay B.T., Ferreira, Vitor F., Camara, Celso A., Valença, Wagner O., de Oliveira, Ronaldo N., Frézard, Frédéric, and da Silva Júnior, Eufrânio N.
- Subjects
- *
NAPHTHOQUINONE , *THERAPEUTIC use of antimony , *LEISHMANIA , *RING formation (Chemistry) , *COPPER catalysts , *ANTIPARASITIC agents , *AZIDE synthesis , *TRIAZOLES , *MEDICAL screening - Abstract
Abstract: Continuing our screening program for novel anti-parasite compounds, we synthesized seven 1,4-naphthoquinones coupled to 1,2,3-triazoles, five nor-β-lapachone-based 1,2,3-triazoles and ten α-lapachone-based 1,2,3-triazoles. These and other naphthoquinonoid compounds were evaluated for their activity against promastigote forms of antimony-sensitive and -resistant strains of Leishmania infantum (syn. Leishmania chagasi) and Leishmania amazonensis. The toxicity of these compounds to mammalian cells was also examined. The substances were more potent than an antimonial drug, with IC50 values ranging from 1.0 to 50.7 μM. Nor-α-lapachone derivatives showed the highest antileishmanial activity, with selectivity indices in the range of 10–15. These compounds emerged as important leads for further investigation as antileishmanial agents. Additionally, one of these compounds exhibited cross-resistance in Sb-resistant Leishmania and could provide a molecular tool for investigating the multidrug resistance mechanisms in Leishmania parasites. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
7. The mutation G133D on Leishmania guyanensis AQP1 is highly destabilizing as revealed by molecular modeling and hypo-osmotic shock assay.
- Author
-
Tunes, Luiza G., Ascher, David B., Pires, Douglas E.V., and Monte-Neto, Rubens L.
- Subjects
- *
MOLECULAR models , *LEISHMANIA , *SMALL molecules , *QUATERNARY structure , *PROTEIN stability - Abstract
The Leishmania aquaglyceroporin 1 (AQP1) plays an important role in osmoregulation and antimony (Sb) uptake, being determinant for resistance to antimony. We have previously demonstrated that G133D mutation on L. guyanensis AQP1 (LgAQP1) leads to reduced Sb uptake. Here, we investigated the effects of G133D mutation on LgAQP1 structure, associated with Sb uptake and alterations in osmoregulation capacity. High confidence molecular models of wild-type LgAQP1 as well as the LgAQP1::G133D mutant were constructed and optimized via comparative homology modeling. Computational methods from the mCSM platform were used to evaluate the effects on protein stability and on its ability to bind to glycerol. Functional validation of the disruptive effect of the mutation on LgAQP1 was done by challenging the parasites with hypo-osmotic chock. Glycine 133 is on transmembrane helix 3, buried in the membrane in both open and closed conformation. G133D mutation was predicted to be highly destabilizing, as it alters the helical bundling arrangement in order to accommodate the aspartic acid side chain. The shift in helices also resulted in fewer favorable contacts with glycerol in the channel, which would explain the reduced affinity for similar small molecules as SbO 3. Under hypo-osmotic condition, L. g uyanensis AQP1G133D presented a 3-fold increase in cellular volume and pronounced delay to recover osmosis homeostasis when compared to the wild-type, a profile that was enhanced in LgAQP1−/− mutants. In conclusion, G133D is a highly disruptive mutation that will destabilize the monomer, compromise tetramer formation and alter pore conformation, leading to reduced Sb uptake and deficient osmoregulation. [Display omitted] • G133D mutation in L. guyanensis AQP1 transmembrane portion is highly destabilizing. • L. guyanensis AQP1 G133D may alter pore forming quaternary structure. • Lg AQP1 G133D alters osmotic control as revealed by hypo-osmotic challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Unveiling six potent and highly selective antileishmanial agents via the open source compound collection 'Pathogen Box' against antimony-sensitive and -resistant Leishmania braziliensis.
- Author
-
Souza Silva, Juliano A., Tunes, Luiza G., Coimbra, Roney S., Ascher, David B., Pires, Douglas E.V., and Monte-Neto, Rubens L.
- Subjects
- *
CUTANEOUS leishmaniasis , *LEISHMANIA , *LEISHMANIASIS , *PATHOGENIC microorganisms , *SMALL molecules , *DRUG counterfeiting , *ISCHEMIC colitis , *RIFAMPIN - Abstract
• 23 pathogen box compounds reduced ≥ 80 % L. braziliensis growth at 5 μM. • Six pathogen box compounds were highly selective with SI ranging from >104 - > 746. • The most active compounds presented IC 50 varying from 47 to 480 nM, being active against Sb-resistant parasites. • Computational prediction revealed CRK3, CYP450 and PKA as L. braziliensis targets for selected compounds. • pkCSM, an ADMET prediction tool can provide clues on further in vivo studies in the context of Pathogen Box. Despite all efforts to provide new chemical entities to tackle leishmaniases, we are still dependent on a the limited drug arsenal, together with drawbacks like toxicity and drug-resistant parasites. Collaborative drug discovery emerged as an option to speed up the way to find alternative antileishmanial agents. This is the case of Medicines for Malaria Ventures - MMV, that promotes an open source drug discovery initiative to fight diseases worldwide. Here, we screened 400 compounds from 'Pathogen Box' (PBox) collection against Leishmania braziliensis , the main etiological agent of cutaneous leishmaniasis in Brazil. Twenty-three compounds were able to inhibit ≥ 80 % L. braziliensis growth at 5 μM. Six out of the PBox selected 23 compounds were found to be highly selective against L. braziliensis intracellular amastigotes with selectivity index varying from > 104 to > 746 and IC 50 s ranging from 47 to 480 nM. The compounds were also active against antimony-resistant L. braziliensis isolated from the field or laboratory selected mutants, revealing the potential on treating patients infected with drug resistant parasites. Most of the selected compounds were known to be active against kinetoplastids, however, two compounds (MMV688703 and MMV676477) were part of toxoplasmosis and tuberculosis 'PBox' disease set, reinforcing the potential of phenotyping screening to unveil drug repurposing. Here we applied a computational prediction of pharmacokinetic properties using the ADMET predictor pkCSM (http://biosig.unimelb.edu.au/pkcsm/). The tool offered clues on potential drug development needs and can support further in vivo studies. Molecular docking analysis identified CRK3 (LbrM.35.0660), CYP450 (LbrM.30.3580) and PKA (LbrM.18.1180) as L. braziliensis targets for MMV676604, MMV688372 and MMV688703, respectively. Compounds from 'Pathogen Box' thus represents a new hope for novel (or repurposed) small molecules source to tackle leishmaniases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.